Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408219 · ClinicalTrials.gov registry record
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
A clinical trial of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 350
- Enrollment target
- 1
- Study location
NCT07408219 is a study of Chronic Spontaneous Urticaria that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 350 participants, below the 1,408-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07408219, a study of Chronic Spontaneous Urticaria, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2026-01-17 |
| Est. Completion | 2026-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07408219
The ClinicalTrials.gov registry entry for NCT07408219 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,408-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (75% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 0 interventions.
NCT07408219 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07408219 about?
NCT07408219 is a clinical study titled "A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients". This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
What is the current status of trial NCT07408219?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2026-01-17. Estimated completion is 2026-03-31.
What conditions does trial NCT07408219 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
Who is sponsoring clinical trial NCT07408219?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07408219 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
Remibrutinib in Real-world Clinical Practice - a US Sub-study
RECRUITING
-
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
RECRUITING · Phase 2
-
Remibrutinib in Real-world Clinical Practice
RECRUITING
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
-
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.